| New markers for separating benign from malignant mesothelial proliferations: are we there yet? A Churg, BS Sheffield, F Galateau-Salle Archives of Pathology and Laboratory Medicine 140 (4), 318-321, 2016 | 190 | 2016 |
| BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations BS Sheffield, HC Hwang, AF Lee, K Thompson, S Rodriguez, ... The American journal of surgical pathology 39 (7), 977-982, 2015 | 187 | 2015 |
| Synchronous endometrial and ovarian carcinomas: evidence of clonality MS Anglesio, YK Wang, M Maassen, HM Horlings, A Bashashati, J Senz, ... Journal of the National Cancer Institute 108 (6), djv428, 2016 | 179 | 2016 |
| Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens HC Hwang, BS Sheffield, S Rodriguez, K Thompson, HT Christopher, ... The American journal of surgical pathology 40 (1), 120-126, 2016 | 174 | 2016 |
| Synthesis of diagnostic quality cancer pathology images by generative adversarial networks AB Levine, J Peng, D Farnell, M Nursey, Y Wang, JR Naso, H Ren, ... The Journal of pathology 252 (2), 178-188, 2020 | 102 | 2020 |
| Preoperative diagnosis of thyroid nodules using the Bethesda System for Reporting Thyroid Cytopathology: a comprehensive review and meta-analysis BS Sheffield, H Masoudi, B Walker, SM Wiseman Expert review of endocrinology & metabolism 9 (2), 97-110, 2014 | 70 | 2014 |
| Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma M Riazy, SE Kalloger, BS Sheffield, RD Peixoto, HH Li-Chang, ... Modern Pathology 28 (10), 1383-1389, 2015 | 68 | 2015 |
| Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice LM Prentice, RR Miller, J Knaggs, A Mazloomian, R Aguirre Hernandez, ... PLoS One 13 (4), e0196434, 2018 | 63 | 2018 |
| Challenges in making the transition between pediatric and adult eating disorder programs: a qualitative study from the perspective of service providers G Dimitropoulos, AF Tran, P Agarwal, B Sheffield, B Woodside Eating disorders 21 (1), 1-15, 2013 | 52 | 2013 |
| HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation BS Sheffield, J Garratt, SE Kalloger, HH Li-Chang, EE Torlakovic, ... Archives of Pathology and Laboratory Medicine 138 (11), 1495-1502, 2014 | 51 | 2014 |
| Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing BS Sheffield, AV Tinker, Y Shen, H Hwang, HH Li-Chang, E Pleasance, ... PLoS One 10 (3), e0119689, 2015 | 48 | 2015 |
| Navigating the transition from pediatric to adult eating disorder programs: perspectives of service providers G Dimitropoulos, AF Tran, P Agarwal, B Sheffield, B Woodside International Journal of Eating Disorders 45 (6), 759-767, 2012 | 48 | 2012 |
| Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma B Tessier-Cloutier, SE Kalloger, M Al-Kandari, K Milne, D Gao, BH Nelson, ... BMC cancer 17, 1-10, 2017 | 43 | 2017 |
| Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer MR Jones, KA Schrader, Y Shen, E Pleasance, C Ch'ng, N Dar, S Yip, ... Annals of Oncology 27 (5), 801-806, 2016 | 43 | 2016 |
| Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor BS Sheffield, Z Kos, K Asleh-Aburaya, XQ Wang, S Leung, D Gao, J Won, ... Breast cancer research and treatment 155, 483-490, 2016 | 39 | 2016 |
| Investigation of PD-L1 biomarker testing methods for PD-1 axis inhibition in non-squamous non–small cell lung cancer BS Sheffield, R Fulton, SE Kalloger, K Milne, G Geller, M Jones, ... Journal of Histochemistry & Cytochemistry 64 (10), 587-600, 2016 | 37 | 2016 |
| Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non–small cell lung cancer D Owen, BS Sheffield, D Ionescu, A Churg Human pathology 60, 82-85, 2017 | 36 | 2017 |
| Point of care molecular testing: community-based rapid next-generation sequencing to support cancer care BS Sheffield, A Beharry, J Diep, K Perdrizet, MAJ Iafolla, W Raskin, ... Current Oncology 29 (3), 1326-1334, 2022 | 33 | 2022 |
| Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer PK Cheema, M Gomes, S Banerji, P Joubert, NB Leighl, B Melosky, ... Current Oncology 27 (6), 321-329, 2020 | 31 | 2020 |
| Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective M Cabanero, R Sangha, BS Sheffield, M Sukhai, M Pakkal, S Kamel-Reid, ... Current Oncology 24 (2), 111-119, 2017 | 30 | 2017 |
